Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §102 only | 1 (20%) |
| §112 only | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FORRY, COLTON BUSA | 1 | — | — |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.3% | +48.6% |
| KIM, TAEYOON | 1 | 51.5% | +51.4% |
| GALSTER, SAMUEL LEONARD | 1 | 53.8% | +39.1% |
| SITTON, JEHANNE SOUAYA | 1 | 52.9% | +47.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18123009 | PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS | TOWNSLEY, SARA ELIZABETH | 83d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18098994 | Development of decellularized bovine bone graft | KIM, TAEYOON | 85d overdue |
| 18088285 | NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2 | GALSTER, SAMUEL LEONARD | 15d |
| 16562861 | DIAGNOSTIC AND PROGNOSTIC LIQUID BIOPSY BIOMARKERS FOR ASTHMA | SITTON, JEHANNE SOUAYA | 28d |
| 18123009 | PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS | TOWNSLEY, SARA ELIZABETH | 83d |
| Art Unit | Apps |
|---|---|
| 1711 | 1 |
| 1629 | 1 |
| 1631 | 1 |
| 1693 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18328419 | Yeast (S. cerevisiae) sheathing through electrochemical discharge of Cobalt air battery | FORRY, COLTON BUSA | 1711 | §112 | Non-Final OA | 16d | Pending | Jun 02, 2023 |
| 18123009 | PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS | TOWNSLEY, SARA ELIZABETH | 1629 | §112 | Non-Final OA | 83d | Pending | Mar 17, 2023 |
| 18098994 | Development of decellularized bovine bone graft | KIM, TAEYOON | 1631 | §103 | Non-Final OA | 85d overdue | Pending | Jan 19, 2023 |
| 18088285 | NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2 | GALSTER, SAMUEL LEONARD | 1693 | §102 | Final Rejection | 15d | Pending | Dec 23, 2022 |
| 16562861 | DIAGNOSTIC AND PROGNOSTIC LIQUID BIOPSY BIOMARKERS FOR ASTHMA | SITTON, JEHANNE SOUAYA | 1682 | §103 | Non-Final OA | 28d | Pending | Sep 06, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial